<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680175</article-id><article-id pub-id-type="doi">10.3390/vaccines12121445</article-id><article-id pub-id-type="publisher-id">vaccines-12-01445</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Benefits of COVID-19 Vaccination for Pregnant Patients Hospitalized with Respiratory Symptoms: A Retrospective Cohort Study in South Brazil</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hernandez</surname><given-names>Christopher J.</given-names></name><xref rid="af1-vaccines-12-01445" ref-type="aff">1</xref><xref rid="c1-vaccines-12-01445" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Sundar</surname><given-names>Kavya G.</given-names></name><xref rid="af2-vaccines-12-01445" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Echegaray</surname><given-names>Fernando</given-names></name><xref rid="af1-vaccines-12-01445" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Cambou</surname><given-names>Mary Catherine</given-names></name><xref rid="af3-vaccines-12-01445" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Lanbo Z.</given-names></name><xref rid="af4-vaccines-12-01445" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3580-7712</contrib-id><name><surname>Segura</surname><given-names>Eddy R.</given-names></name><xref rid="af5-vaccines-12-01445" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Gon&#x000e7;alves de Melo</surname><given-names>Marineide</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af6-vaccines-12-01445" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Santos</surname><given-names>Breno Riegel</given-names></name><xref rid="af6-vaccines-12-01445" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Varella</surname><given-names>Ivana Ros&#x000e2;ngela dos Santos</given-names></name><xref rid="af6-vaccines-12-01445" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1742-5211</contrib-id><name><surname>Nielsen-Saines</surname><given-names>Karin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af7-vaccines-12-01445" ref-type="aff">7</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>La Torre</surname><given-names>Giuseppe</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01445"><label>1</label>UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA; <email>fechegaray@mednet.ucla.edu</email></aff><aff id="af2-vaccines-12-01445"><label>2</label>Cooper Medical School of Rowan University, Camden, NJ 08103, USA; <email>kavyagsundar@gmail.com</email></aff><aff id="af3-vaccines-12-01445"><label>3</label>Division of Infectious Diseases, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA; <email>mcambou@mednet.ucla.edu</email></aff><aff id="af4-vaccines-12-01445"><label>4</label>Department of Obstetrics and Gynecology, Tulane University School of Medicine, New Orleans, LA 70112, USA; <email>lanbo_yang@brown.edu</email></aff><aff id="af5-vaccines-12-01445"><label>5</label>Facultad de Ciencias de la Salud, Universidad Cient&#x000ed;fica del Sur, Panamericana Sur Km 19, Villa, Lima 15067, Peru; <email>eddysegura@gmail.com</email></aff><aff id="af6-vaccines-12-01445"><label>6</label>Hospital Nossa Senhora da Concei&#x000e7;&#x000e3;o, Tubar&#x000e3;o 88701-160, Brazil; <email>rmarineide@ghc.com.br</email> (M.G.d.M.); <email>breno@ghc.com.br</email> (B.R.S.); <email>vivana@ghc.com.br</email> (I.R.d.S.V.)</aff><aff id="af7-vaccines-12-01445"><label>7</label>Division of Pediatric Infectious Diseases, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA; <email>knielsen@mednet.ucla.edu</email></aff><author-notes><corresp id="c1-vaccines-12-01445"><label>*</label>Correspondence: <email>christopherhernandez@mednet.ucla.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1445</elocation-id><history><date date-type="received"><day>31</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>13</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Objectives: SARS-CoV-2 infection is a known risk factor for adverse health outcomes in pregnancy, affecting both maternal and neonatal health. Mounting evidence suggests that even a single dose of an approved COVID-19 vaccine protects against severe SARS-CoV-2 infection and is safe for both pregnant persons and neonates. Southern Brazil was heavily affected by the COVID-19 pandemic, and the protective effects of the vaccine on maternal and neonatal health are not well described. This study aims to examine the protective effects of maternal COVID-19 vaccination on both maternal and neonatal outcomes following SARS-CoV-2 infection during pregnancy. Methods: This is a retrospective cohort study that leveraged medical data from a tertiary center in South Brazil to compare maternal and infant outcomes between hospitalized pregnant persons with and without SARS-CoV-2 infection between 1 March 2020, and 1 March 2023. Results: In total, 524 patients were enrolled, including 275 pregnant patients with confirmed SARS-CoV-2 infection and 249 without infection. SARS-CoV-2 infection was associated with maternal ventilator support (adjusted Risk Ratio [aRR] = 1.48, 95% Confidence Interval [95% CI]: 1.08&#x02013;2.03), while receipt of at least one dose of COVID-19 vaccine was associated with protection against maternal sepsis (aRR = 0.14, 95% CI: 0.03&#x02013;0.56), intensive care unit (ICU) admission (aRR = 0.27, 95% CI: 0.10&#x02013;0.68), need for ventilator support (aRR = 0.60, 95% CI: 0.43&#x02013;0.84), infant admission to the neonatal intensive care unit (NICU) (aRR = 0.62, 95% CI: 0.47&#x02013;0.82), and neonatal respiratory distress (aRR = 0.60, 95% CI: 0.43&#x02013;0.83). Conclusions: These findings further underscore the importance of maternal vaccination against COVID-19 during pregnancy. Even one dose of vaccine was protective against a variety of maternal and neonatal outcomes. Prenatal care should encourage COVID-19 vaccination in pregnancy.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>vaccination</kwd><kwd>pregnancy outcomes</kwd></kwd-group><funding-group><award-group><funding-source>National Institutes of Health/National Institute of Mental Health</funding-source><award-id>R25 MH08722</award-id></award-group><funding-statement>This research was supported by the University of California, Los Angeles, South American Program in HIV Prevention Program, National Institutes of Health/National Institute of Mental Health (grant number R25 MH08722). The funders had no role in the study design, data collection, and analysis.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01445"><title>1. Introduction</title><p>Brazil holds one of the highest total mortalities due to COVID-19, with geographically distinct patterns of incidence, morbidity, and mortality rates [<xref rid="B1-vaccines-12-01445" ref-type="bibr">1</xref>]. The state of Rio Grande do Sul, for example, reached an incidence rate of 4472 per 100,000 people, an incidence higher than the national average of 3129 per 100,000 people. However, the mortality rate of the state was lower, standing at 81 per 100,000 compared to the national average of 84 per 100,000 [<xref rid="B1-vaccines-12-01445" ref-type="bibr">1</xref>]. Despite this, Rio Grande do Sul and the state capital of Porto Alegre had the highest total mortality among the southern states of Brazil [<xref rid="B2-vaccines-12-01445" ref-type="bibr">2</xref>]. Brazil also documented an exceedingly high mortality figure among pregnant and post-partum individuals. Reflecting this, the maternal mortality rate increased among all states in Brazil by the end of 2021, with the south holding a lower maternal mortality rate compared to other regions in Brazil [<xref rid="B3-vaccines-12-01445" ref-type="bibr">3</xref>]. As of 2022, Rio Grande do Sul has the 6th highest human development index across the 26 states of Brazil, which may have translated into more prompt access to higher quality healthcare among pregnant people with COVID-19 [<xref rid="B4-vaccines-12-01445" ref-type="bibr">4</xref>]. This underscores the importance of describing the regional patterns of COVID-19 incidence, vaccine uptake, and potential associated socio-demographics.</p><p>Pregnancy is a well-documented risk factor for severe and critical COVID-19 [<xref rid="B5-vaccines-12-01445" ref-type="bibr">5</xref>]. Compared with non-pregnant patients, higher rates of ICU admission and requirements for invasive ventilation have been observed among pregnant women who are hospitalized with SARS-CoV-2 infection [<xref rid="B6-vaccines-12-01445" ref-type="bibr">6</xref>]. Normal physiological changes during pregnancy, including changes to the immune system, increased cardiovascular requirements, and decreased lung capacity potentially contribute to the increased susceptibility to severe disease, evidenced by a greater risk for adverse outcomes during the later stages of pregnancy, when the most profound changes take place [<xref rid="B7-vaccines-12-01445" ref-type="bibr">7</xref>]. Further, COVID-19 has been associated with greater rates of pregnancy complications. Compared to pregnant women with asymptomatic or mild SARS-CoV-2 infection, women with severe COVID-19 have been shown to have increased rates of preterm delivery [<xref rid="B8-vaccines-12-01445" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-12-01445" ref-type="bibr">9</xref>]. In addition, a study of 200 pregnant women with SARS-CoV-2 infection reported that a large number of neonates born to mothers with moderate to severe COVID-19 were admitted to the neonatal intensive care unit (NICU) [<xref rid="B10-vaccines-12-01445" ref-type="bibr">10</xref>].</p><p>COVID-19 vaccination has been shown to be a safe and effective way to prevent severe COVID-19 in pregnancy, although uptake among pregnant persons in Brazil remains subpar due to fear surrounding both maternal and neonatal side effects. A study in Rio de Janeiro, Brazil examining 17,513 live births between 15 May 2021 and 23 October 2021 demonstrated that maternal COVID-19 vaccination was safe, as it was not associated with preterm birth, small for gestational age events, low birth weight, low Apgar scores, or death [<xref rid="B11-vaccines-12-01445" ref-type="bibr">11</xref>]. In terms of efficacy, a prospective cohort study conducted in Rio de Janeiro found that mothers who were vaccinated with at least one dose were significantly less likely to have severe morbidity and mortality associated with SARS-CoV-2 infection [<xref rid="B12-vaccines-12-01445" ref-type="bibr">12</xref>]. A systematic review of 30 studies involving 862,272 pregnant patients (308,428 vaccinated and 553,844 unvaccinated) found that COVID-19 vaccination during pregnancy reduced COVID-19 disease severity and was not associated with any adverse maternal and neonatal outcomes [<xref rid="B13-vaccines-12-01445" ref-type="bibr">13</xref>]. As such, the current guidelines set out by the Brazilian Obstetrics Society and the American College of Obstetrics and Gynecologists recommend that all pregnant patients complete the vaccination series at any point during pregnancy [<xref rid="B14-vaccines-12-01445" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-12-01445" ref-type="bibr">15</xref>].</p><p>The objective of the present study was twofold: (1) to analyze the associations of adverse maternal and neonatal outcomes in pregnant patients hospitalized with respiratory symptoms with and without SARS-CoV-2 infection in a cohort of pregnant patients in south Brazil, and (2) to estimate the uptake and protective effects of COVID-19 vaccination among this cohort. A significant novelty of this study is the control population, which includes pregnant people with respiratory symptoms that could be explained by viruses other than SARS-CoV-2, which may also be associated with adverse maternal outcomes.</p></sec><sec sec-type="methods" id="sec2-vaccines-12-01445"><title>2. Methods</title><sec id="sec2dot1-vaccines-12-01445"><title>2.1. Study Site</title><p>This retrospective cohort study spanning 1 March 2020 to 1 March 2023 was performed at a tertiary healthcare center in South Brazil that provides specialized care for medium- and high-risk pregnancies in a low-income region of the city of Porto Alegre, in the state of Rio Grande do Sul. Approximately 3500 deliveries occur at this institution per year.</p></sec><sec id="sec2dot2-vaccines-12-01445"><title>2.2. Patient Selection and Data Sources</title><p>This is a retrospective cohort study of pregnant patients at a reference institution who were tested for SARS-CoV-2 infection. Patients had to be hospitalized at this institution at any point during their pregnancy and had to be reported to one of the two notification systems during their hospital stay (either the SIVEP-Gripe or E-SUS Notifica system) [<xref rid="B16-vaccines-12-01445" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-12-01445" ref-type="bibr">17</xref>]. There were two possible timepoints at which patient medical records and clinical information were accessed. The first timepoint, and not mandatory for inclusion, was the date of hospitalization for any obstetric or clinical reason prior to delivery that was reported to the SIVEP-Gripe or E-SUS Notifica systems. The second timepoint, and mandatory for inclusion in this study, was at the time of delivery. The hospitalization for delivery had to be reported via SIVEP-Gripe or E-SUS Notifica if the patients did not have a previously notified hospitalization during that pregnancy. That is, patients had to be reported to SIVEP-Gripe or E-SUS Notifica at least once during pregnancy: (1) during a hospitalization prior to delivery or (2) at the time of delivery. If a patient had more than one hospitalization during pregnancy recorded in the notification systems, we chose data from the hospitalization associated with a laboratory-confirmed SARS-CoV-2 infection. If all SARS-CoV-2 tests were negative among patients with respiratory symptoms, we chose the hospitalization closest to delivery. Nasopharyngeal specimen testing for SARS-CoV-2 real-time reverse transcription polymerase chain reaction (RT-PCR) or a rapid antigen detection test were used to confirm infection. Patients who met these criteria but did not deliver at the study site were excluded because we did not have access to the outcome information regarding their delivery and post-partum period.</p><p>To calculate the sample sizes needed for this study, we assumed a two-sided significance level of 0.05, a power (1-beta) level of 0.8, an approximate ratio of unexposed to exposed of 1:1, a baseline probability of adverse events in the unexposed group of 0.01, and a relative risk of adverse outcomes for those exposed to SARS-CoV-2 infection of approximately 5 [<xref rid="B8-vaccines-12-01445" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-12-01445" ref-type="bibr">9</xref>]. Based on this, we calculated an approximate requirement of 285 patients per group.</p><p>The SIVEP-Gripe and E-SUS Notifica systems are public surveillance databases for respiratory infections and notifiable diseases from the Brazilian Unified Single Health System (SUS) to which medical institutions of the Single Unified Health System report to, as in the case of our institution. The two notification systems were used prior to March 1st, 2021: only pregnant patients with symptoms of respiratory infection were routinely tested for COVID-19, potentially leaving out asymptomatic SARS-CoV-2 cases from the database. After the emergence of the gamma variant in Brazil in January 2021, guidelines to test all pregnant patients for SARS-CoV-2 infection were put in place. The SIVEP-Gripe holds demographic and clinical history for all patients hospitalized with respiratory symptoms or acute respiratory distress syndrome (ARDS) regardless of SARS-CoV-2 infection [<xref rid="B16-vaccines-12-01445" ref-type="bibr">16</xref>]. The E-SUS Notifica system includes demographic and clinical history for patients with any respiratory symptoms during hospitalization, whether they were SARS-CoV-2 positive or negative, or if they had asymptomatic SARS-CoV-2 infection [<xref rid="B17-vaccines-12-01445" ref-type="bibr">17</xref>].</p></sec><sec id="sec2dot3-vaccines-12-01445"><title>2.3. COVID-19 Vaccination</title><p>In March 2021, the Brazilian Ministry of Health authorized SARS-CoV-2 vaccination for pregnant women with comorbidities. Initially, the CoronaVac (whole inactivated SARS-CoV-2, Sinovac Biotech/Butantan Institute, S&#x000e3;o Paulo, Brazil), the AstraZeneca adenovirus viral vector vaccine (Oxford/Biomanguinhos, Rio de Janeiro, Brazil), Janssen adenovirus viral vector vaccine (Johnson and Johnson/Janssen Pharmaceuticals, Leiden, The Netherlands) and the BNT162b2 mRNA vaccine (Pfizer-BioNTech, Kalamazoo, MI, USA) were authorized for use in Brazil. In mid-May 2021, the Ministry of Health halted administration of the AstraZeneca vaccine to pregnant women due to a cardiovascular accident event that occurred in a pregnant patient after vaccination [<xref rid="B18-vaccines-12-01445" ref-type="bibr">18</xref>]. In late June 2021, COVID-19 vaccination was made available to all pregnant women in Brazil, regardless of comorbid conditions. In September 2021, the Ministry of Health recommended that pregnant women should receive either BNT162b2 or CoronaVac.</p></sec><sec id="sec2dot4-vaccines-12-01445"><title>2.4. Demographic and Clinical Measurements</title><p>The co-variates analyzed were age, race, geographical region of residence, trimester of pregnancy at time of hospitalization, caesarean delivery, multiparity, maternal comorbidities, and history of at least one dose of the COVID-19 vaccine. These variables were selected because they are known causes of maternal mortality in low-income countries, and because they have been investigated in previous studies of risk factors for severe morbidity and mortality among women with SARS-CoV-2 infection during pregnancy [<xref rid="B19-vaccines-12-01445" ref-type="bibr">19</xref>].</p></sec><sec id="sec2dot5-vaccines-12-01445"><title>2.5. Clinical Outcomes</title><p>The primary outcomes related to severe maternal morbidity were defined as ICU admission or need for ventilator support. Pregnancy outcomes included hypertensive disorders of pregnancy, maternal sepsis, postpartum hemorrhage, preterm birth (defined as gestational age at time of delivery less than 37 weeks), stillbirth (&#x0003e;=20 weeks), or miscarriage (&#x0003c;20 weeks). Maternal mortality, defined as death during the hospitalization or up to 42 days postpartum, was described; however, all instances of mortality occurred among patients who were admitted to the ICU and were considered within that outcome in the analysis. Neonatal outcomes included birthweight, NICU admission, or neonatal respiratory distress.</p></sec><sec id="sec2dot6-vaccines-12-01445"><title>2.6. Statistical Analysis</title><p>Descriptive statistics were reported for demographic and clinical data. Bivariate associations between SARS-CoV-2 infection and demographic, clinical data, and selected maternal and neonatal outcomes were assessed by conducting Chi-square tests of independence comparing categorical (e.g., SARS-CoV-2 infection distribution differences among rural vs. urban vs. greater metropolitan region) or dichotomous (e.g., SARS-CoV-2 infection distribution differences among smokers vs. non-smokers) variable exposures. Bivariate modified Poisson regressions between outcomes of interest and SARS-CoV-2 infection were conducted to assess magnitude of association [<xref rid="B20-vaccines-12-01445" ref-type="bibr">20</xref>]. A multivariable modified Poisson regression analysis was performed for each maternal or neonatal clinical outcome of interest, with the primary exposure variables being SARS-CoV-2 infection during hospitalization and receipt of at least one dose of COVID-19 vaccine, further controlling for age, parity, gestational age, and composite score of preexisting comorbidities [<xref rid="B21-vaccines-12-01445" ref-type="bibr">21</xref>]. Models were checked for model fitness and collinearity. Significant independent associations between the maternal or neonatal clinical outcome of interest and SARS-CoV-2 infection or receipt of at least one dose of COVID-19 vaccine were reported. Patients with missing data or who did not have information for a given outcome were excluded from the pertinent models. A sensitivity analysis looking at two doses of vaccination was conducted following same steps as above. Statistical analysis was performed using STATA 14.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-12-01445"><title>3. Results</title><sec id="sec3dot1-vaccines-12-01445"><title>3.1. Socio-Demographics</title><p>In total, 810 pregnant or immediately post-partum patients hospitalized at any time during pregnancy at the participating institution and tested for SARS-CoV-2 infection were potential study candidates. Among these, 390 participants tested positive for SARS-CoV-2 and 420 tested negative (<xref rid="vaccines-12-01445-f001" ref-type="fig">Figure 1</xref>). In total, 524 participants were ultimately enrolled in the study because they delivered at the participating institution and had primary outcome data available. This included 275 participants with laboratory-confirmed SARS-CoV-2 infection during pregnancy and 249 who tested negative. Among participants delivering at the tertiary healthcare center, most (76%) were between 18 and 34 years of age, 20% were 35 years of age or over, and a minority (4%) were under the age of 18 (<xref rid="vaccines-12-01445-t001" ref-type="table">Table 1</xref>). The majority of participants (68%) identified as White, a fifth (20%) identified as Black, and 13% identified as multiracial. Over half (51%) of patients had completed less than high school, 41% completed high school, 8% had a university degree, and less than 1% did not report level of education. Most patients (72%) resided in the urban region of Porto Alegre, while 24% came from the greater metropolitan region, and 4% from a rural region. The most common preexisting comorbidities included obesity at 22%, hypertension at 19%, and present or history of smoking at 18%. Most (66%) patients were multigravida and 46% underwent a C-section during delivery.</p><sec id="sec3dot1dot1-vaccines-12-01445"><title>3.1.1. SARS-CoV-2 Infection</title><p>Among participants with laboratory-confirmed SARS-CoV-2 infection, 22% were asymptomatic, 51% had mild to moderate disease, and 27% had severe to critical disease (<xref rid="app1-vaccines-12-01445" ref-type="app">Supplementary Table S1</xref>). Fifty percent of those with mild to moderate disease compared to 77% of those with severe to critical disease had had not received a single dose of the COVID-19 vaccine (<italic toggle="yes">p</italic> &#x0003c; 0.001).</p></sec><sec id="sec3dot1dot2-vaccines-12-01445"><title>3.1.2. COVID-19 Vaccination</title><p>Forty-eight percent of the cohort had received at least one dose of the COVID-19 vaccine at the time of hospitalization. Among those vaccinated (n = 252), the most common vaccine used was BNT162b2 mRNA vaccine (Pfizer-BioNTech, Kalamazoo, MI, USA) at 68.3%, followed by CoronaVac (whole inactivated SARS-CoV-2, Sinovac Biotech/Butantan Institute, S&#x000e3;o Paulo, Brazil), at 19.0 AstraZeneca adenovirus viral vector vaccine (Oxford/Biomanguinhos, Rio de Janeiro, Brazil), at 11.5%, and the Janssen adenovirus viral vector vaccine (Johnson and Johnson/Janssen Pharmaceuticals, Leiden, The Netherlands) at 1.2%.</p></sec></sec><sec id="sec3dot2-vaccines-12-01445"><title>3.2. Bivariate Associations</title><p>Socio-economic factors associated with SARS-CoV-2 infection included region of residence, with higher positivity seen in patients coming from rural regions (7% positives vs. 1%, negatives <italic toggle="yes">p</italic> = 0.001) or the greater metropolitan area (26% positives vs. 22% negatives, <italic toggle="yes">p</italic> = 0.001), while in urban areas, a higher frequency of negative patients was seen (67% positives vs. 77% negatives, <italic toggle="yes">p</italic> = 0.0001), likely reflective of hospital referral patterns. Interestingly, SARS-CoV-2 positive patients were less likely to smoke than negative patients (12% vs. 24%, <italic toggle="yes">p</italic> = 0.001; <xref rid="vaccines-12-01445-t001" ref-type="table">Table 1</xref>). Further, maternal ICU admission (9% vs. 4%, <italic toggle="yes">p</italic> = 0.048), ventilator support (27 vs. 18%, <italic toggle="yes">p</italic> = 0.005), and NICU admission (36% vs. 27%, <italic toggle="yes">p</italic> = 0.026) were associated with SARS-CoV-2 infection (<xref rid="vaccines-12-01445-t002" ref-type="table">Table 2</xref>). There were five cases of maternal mortality, and all occurred among patients who were admitted to the ICU. Four deaths occurred among those with SARS-CoV-2, and one occurred among SARS-CoV-2 negative patients.</p></sec><sec id="sec3dot3-vaccines-12-01445"><title>3.3. Multivariable Associations</title><p>At the multivariable level (<xref rid="vaccines-12-01445-t003" ref-type="table">Table 3</xref>), ventilator support was found to be independently associated with SARS-CoV-2 infection (adjusted Risk Ratio [aRR] = 1.48, 95% Confidence Interval [95% CI] = 1.08&#x02013;2.03). We found that receipt of at least one dose of COVID-19 vaccination was associated with lower risk of maternal sepsis (aRR = 0.14, 95% CI 0.03&#x02013;0.56), lower risk of ICU admission (aRR = 0.27, 95% CI 0.10&#x02013;0.68), lower risk of ventilator support (aRR = 0.60, 95% CI 0.43&#x02013;0.84), lower risk of NICU admission (aRR = 0.62, 95% CI 0.47&#x02013;0.82), and lower risk of neonatal respiratory distress (aRR = 0.60, 95% CI 0.43&#x02013;0.83). In the sensitivity analysis, receipt of at least two doses of COVID-19 vaccination was largely comparable to receipt of one vaccine dose (<xref rid="app1-vaccines-12-01445" ref-type="app">Supplementary Table S2</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-12-01445"><title>4. Discussion</title><p>We found important associations between adverse maternal and neonatal outcomes and maternal SARS-CoV-2 infections during pregnancy among hospitalized pregnant persons at a large tertiary healthcare center in south Brazil. Pregnant patients who were admitted to the ICU or required ventilator support were more likely to have been diagnosed with SARS-CoV-2 infection; however, only ventilator support was independently associated with SARS-CoV-2 infection. We found that slightly less than half of patients had at least one dose of COVID-19 vaccination, with vaccination being associated with a significantly reduced risk for multiple maternal and neonatal outcomes. Most patients in this study did not have COVID-19 vaccination at the time of hospitalization, and accounted for the greatest proportion of those who presented with mild to moderate or severe to critical SARS-CoV-2 disease severity. Maternal vaccination was independently associated with a significant risk reduction for maternal sepsis, ICU admission, and need for ventilator support. Maternal receipt of at least one COVID-19 vaccine dose protected against NICU admission and neonatal respiratory distress. C-sections in this study were high, consistent with studies that suggest Brazil is one of the countries with the highest rate of C-sections in the world [<xref rid="B22-vaccines-12-01445" ref-type="bibr">22</xref>].</p><p>Our findings are broadly consistent with multiple studies that have noted increased rates of adverse maternal outcomes among hospitalized pregnant women with SARS-CoV-2 infection [<xref rid="B23-vaccines-12-01445" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01445" ref-type="bibr">24</xref>]. SARS-CoV-2 infection in pregnancy can lead to worsened outcomes, as the natural physiological, endocrinological, and immunological changes associated with pregnancy may predispose patients to respiratory failure in the setting of certain viral infections, including influenza [<xref rid="B25-vaccines-12-01445" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-01445" ref-type="bibr">26</xref>]. In fact, a metanalysis study found that compared to women who were not pregnant, pregnant women with SARS-CoV-2 infection were found to have increased rates of ICU admission and requirements for invasive mechanical intervention, further highlighting the predisposition to acute adverse outcomes in pregnancy [<xref rid="B6-vaccines-12-01445" ref-type="bibr">6</xref>].</p><p>We found that maternal infection was associated with NICU admission, even though vertical transmission rates of SARS-CoV-2 are generally very low, estimated to be less than 2% [<xref rid="B27-vaccines-12-01445" ref-type="bibr">27</xref>]. Changes to the maternal inflammatory profile seen in SARS-CoV-2 infection during pregnancy may explain this association. A recent study found that neonates born to mothers with SARS-CoV-2 infection in pregnancy had a similar immune profile to adults living with COPD in the absence of vertical transmission of SARS-CoV-2 to the neonate [<xref rid="B10-vaccines-12-01445" ref-type="bibr">10</xref>]. An earlier study from our group identified significant inflammatory pathways in pregnant mothers and their newborn infants, despite none of the latter being infected with SARS-CoV-2 and inflammatory cytokines and chemokines not crossing the placenta and being unique in exposed infants [<xref rid="B28-vaccines-12-01445" ref-type="bibr">28</xref>]. Further, a study examining pathological changes to the placenta of mothers infected with SARS-CoV-2 during the third trimester found increased features of abnormal maternal vascular perfusion, suggesting a separate mechanism by which neonatal outcomes could be altered, although in our study, trimester of infection was not found to have a significant association with infant respiratory distress [<xref rid="B29-vaccines-12-01445" ref-type="bibr">29</xref>]. Regardless, these data add to a body of growing literature that implicates maternal SARS-CoV-2 infection in the development of adverse neonatal outcomes and highlights the need to increase prevention and early management of SARS-CoV-2 infection during pregnancy to optimize outcomes.</p><p>Interestingly, although maternal SARS-CoV-2 infection rates did not differ based on maternal vaccination status, our study found that vaccination was protective against multiple adverse maternal and neonatal outcomes. Consistent with the US Centers for Disease Control, we found that vaccination does not necessarily prevent infection, but does protect against severe disease [<xref rid="B30-vaccines-12-01445" ref-type="bibr">30</xref>]. Studies have found that waning humoral immunity and viral evolution may allow for viral escape, but anamnestic T cell responses to conserved viral epitopes prevent severe infection [<xref rid="B31-vaccines-12-01445" ref-type="bibr">31</xref>]. As such, our data are consistent with a longitudinal cohort study in Rio de Janeiro which found that the risk for severe maternal morbidity and mortality was significantly reduced when patients were vaccinated [<xref rid="B12-vaccines-12-01445" ref-type="bibr">12</xref>]. Similarly, maternal sepsis, which arises when an immune response towards an infection or toxin is dysregulated [<xref rid="B32-vaccines-12-01445" ref-type="bibr">32</xref>], was less likely to occur among pregnant patients who were vaccinated. Vaccination may have provided a more measured immune response to SARS-CoV-2 infection, which reduced the inflammatory burden and lowered the risk for meeting criteria for sepsis. Consistent with the study as well, we found that maternal vaccination rates were suboptimal, which was due to the lack of availability of vaccines and lack of early guidelines recommending immunization of pregnant women. Vaccines only became available to most pregnant patients in April of 2021, with more prominent immunization of pregnant women occurring in the second half of 2021. We found, however, that maternal vaccination not only confers protection to the mother, but also to the neonate, and was not related to any adverse maternal or neonatal outcomes in our study. Vaccination may confer protection to the neonate by preventing aberrant changes to the cytokine profile as discussed above, leading to reduced rates of respiratory complications. Transplacental transfer of maternal anti-SARS-CoV-2 IgG antibodies is significantly enhanced after vaccination (hybrid immunity), which could also play a protective role for the neonate, conferring protection until the infant is at least 6 months of age and then able to be immunized [<xref rid="B33-vaccines-12-01445" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-12-01445" ref-type="bibr">34</xref>]. Further, a study found that maternal vaccination with two doses of mRNA vaccine was associated with a reduced risk of hospitalization for COVID-19, including for critical illness, among infants younger than 6 months of age [<xref rid="B35-vaccines-12-01445" ref-type="bibr">35</xref>]. These results indicate that, in this population, vaccination against COVID-19 is a safe and effective strategy to reduce maternal and neonatal morbidity.</p></sec><sec id="sec5-vaccines-12-01445"><title>5. Limitations</title><p>There are important limitations to consider when examining these data. The first limitation is the retrospective nature of the study, with data derived from patients who were hospitalized for any reason at some point during pregnancy. The guidelines set by the Brazilian Ministry of Health evolved throughout the pandemic as new understandings emerged, changing the case definitions of symptomatic disease. Due to temporal changes in SARS-CoV-2 screening, there were likely eligible patients who were not reported to the SIVEP-Gripe notification system. This is particularly true from the start of the pandemic to March 2021, when only pregnant women with respiratory symptoms were tested for SARS-CoV-2 infection, likely leading to missed asymptomatic diagnoses. Similarly, we were limited to SARS-CoV-2 screening tests provided when women were hospitalized, often at the time of delivery. We could not determine if there were SARS-CoV-2 screens or if there was COVID-19 disease at home throughout their pregnancy. These two limitations may affect the internal validity of this study, as pregnant woman who did have SARS-CoV-2 infection were not categorized as exposed. We were also unable to control for a previous SARS-CoV-2 infection, which may have conferred a degree of protection against subsequent disease severity. We were unable to conduct a more granular analysis comparing the various types of vaccinations that were provided because of the small sample size, and had to collapse vaccination categories into vaccinated vs. unvaccinated. The temporal spread of SARS-CoV-2 and COVID-19 vaccination in this study presents further limitations. The earlier period had a largely na&#x000ef;ve population that was not exposed to SARS-CoV-2 through infection or vaccine, which could have disproportionately affected health outcomes. Survivor bias in the later years, such as late 2022 or early 2023, could mean that adverse outcomes in this time period were less frequent as more and more people gained immunity through infection or vaccine. Finally, the nature of our population, pregnant women being served at a public healthcare institution in south Brazil, may overrepresent women of lower socio-economic status facing unique structural, economic, social, and cultural contexts that limit the generalizability of this study to other populations.</p></sec><sec sec-type="conclusions" id="sec6-vaccines-12-01445"><title>6. Conclusions</title><p>This study among hospitalized pregnant patients with respiratory symptoms further characterizes the impact of SARS-CoV-2 infection in pregnancy compared to other respiratory infections and highlights that maternal receipt of at least one dose of a COVID-19 vaccine was protective against multiple adverse maternal and neonatal outcomes. Maternal vaccination against SARS-CoV-2 was again proven to be very safe and extremely effective in the reduction of maternal and neonatal morbidity and mortality risk, highlighting the need for this practice to be highly encouraged in pregnant patients.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-12-01445"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines12121445/s1">https://www.mdpi.com/article/10.3390/vaccines12121445/s1</uri>, Table S1: Association between COVID-19 disease severity and receipt of at least one dose of SARS-CoV-2 vaccine. Table S2: Selected outcomes and their association with maternal reciept of at least two COVID-19 vaccines at the time of hospitalization.</p><supplementary-material id="vaccines-12-01445-s001" position="float" content-type="local-data"><media xlink:href="vaccines-12-01445-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, C.J.H.; Methodology, C.J.H., E.R.S. and K.N.-S.; Software, E.R.S.; Formal analysis, C.J.H. and E.R.S.; Investigation, K.G.S., F.E., M.C.C., I.R.d.S.V., L.Z.Y. and B.R.S.; Resources, I.R.d.S.V., M.G.d.M. and B.R.S.; Data curation, C.J.H., K.G.S., F.E., L.Z.Y. and M.G.d.M.; Writing&#x02014;original draft, C.J.H. and K.N.-S.; Writing&#x02014;review &#x00026; editing, K.G.S., F.E., M.C.C., L.Z.Y., E.R.S. and I.R.d.S.V.; Supervision, M.C.C., M.G.d.M., B.R.S., I.R.d.S.V. and K.N.-S.; Project administration, M.G.d.M. and I.R.d.S.V.; Funding acquisition, I.R.d.S.V. and K.N.-S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was reviewed and approved by the Concei&#x000e7;&#x000e3;o Hospital Ethics Committee (protocol #14.124). </p></notes><notes><title>Informed Consent Statement</title><p>As this was a retrospective analysis of participants reported to public deidentified databases, waiver of written informed consent was granted.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author due to confidentiality concerns as this was a relatively small sample of PPLH in a specific region. </p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>All authors deny any conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01445"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>da Silva</surname><given-names>C.G.</given-names></name>
<name><surname>Daboin</surname><given-names>B.E.G.</given-names></name>
<name><surname>de Mello Monteiro</surname><given-names>C.B.</given-names></name>
</person-group><article-title>Analysis of incidence, mortality and lethality by COVID-19 in the States of Par&#x000e1; and Rio Grande do Sul, Brazil: Epidemiological aspects of evolution 2020&#x02013;2022</article-title><source>J. Hum. Growth Dev.</source><year>2023</year><volume>33</volume><fpage>431</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.36311/jhgd.v33.15287</pub-id></element-citation></ref><ref id="B2-vaccines-12-01445"><label>2.</label><element-citation publication-type="gov"><article-title>BOLETIM EPIDEMIOL&#x000d3;GICO ESPECIAL&#x02014;Secretaria de Vigil&#x000e2;ncia em Sa&#x000fa;de&#x02014;Minist&#x000e9;rio da Sa&#x000fa;de</article-title><comment>Available online: <ext-link xlink:href="https://www.gov.br" ext-link-type="uri">https://www.gov.br</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-15">(accessed on 15 May 2024)</date-in-citation></element-citation></ref><ref id="B3-vaccines-12-01445"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carvalho</surname><given-names>I.C.</given-names></name>
<name><surname>Mascarenhas</surname><given-names>M.D.</given-names></name>
<name><surname>Rodrigues</surname><given-names>M.T.</given-names></name>
<name><surname>Andrade</surname><given-names>J.X.</given-names></name>
<name><surname>Nascimento</surname><given-names>F.F.</given-names></name>
<name><surname>Penha</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Impact of the COVID-19 pandemic on the maternal mortality rate in Brazil: Trend and spatial distribution</article-title><source>Rev. Ga&#x000fa;cha Enferm.</source><year>2024</year><volume>45</volume><fpage>e20230299</fpage><pub-id pub-id-type="doi">10.1590/1983-1447.2024.20230299.pt</pub-id><pub-id pub-id-type="pmid">39607241</pub-id>
</element-citation></ref><ref id="B4-vaccines-12-01445"><label>4.</label><element-citation publication-type="webpage"><article-title>Atlas do Desenvolvimento Humano no Brasil. AtlasBR</article-title><comment>Available online: <ext-link xlink:href="http://www.atlasbrasil.org.br/ranking" ext-link-type="uri">http://www.atlasbrasil.org.br/ranking</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-05">(accessed on 5 December 2024)</date-in-citation></element-citation></ref><ref id="B5-vaccines-12-01445"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Di Mascio</surname><given-names>D.</given-names></name>
<name><surname>Khalil</surname><given-names>A.</given-names></name>
<name><surname>Saccone</surname><given-names>G.</given-names></name>
<name><surname>Rizzo</surname><given-names>G.</given-names></name>
<name><surname>Buca</surname><given-names>D.</given-names></name>
<name><surname>Liberati</surname><given-names>M.</given-names></name>
<name><surname>Vecchiet</surname><given-names>J.</given-names></name>
<name><surname>Nappi</surname><given-names>L.</given-names></name>
<name><surname>Scambia</surname><given-names>G.</given-names></name>
<name><surname>Berghella</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: A systematic review and meta-analysis</article-title><source>Am. J. Obstet. Gynecol. MFM</source><year>2020</year><volume>2</volume><fpage>100107</fpage><pub-id pub-id-type="doi">10.1016/j.ajogmf.2020.100107</pub-id><pub-id pub-id-type="pmid">32292902</pub-id>
</element-citation></ref><ref id="B6-vaccines-12-01445"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>D.S.A.</given-names></name>
<name><surname>Pirzada</surname><given-names>A.N.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
<name><surname>Salam</surname><given-names>R.A.</given-names></name>
<name><surname>Das</surname><given-names>J.K.</given-names></name>
<name><surname>Lassi</surname><given-names>Z.S.</given-names></name>
</person-group><article-title>The Differences in Clinical Presentation, Management, and Prognosis of Laboratory-Confirmed COVID-19 between Pregnant and Non-Pregnant Women: A Systematic Review and Meta-Analysis</article-title><source>Int. J. Environ. Res. Public Health</source><year>2021</year><volume>18</volume><elocation-id>5613</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph18115613</pub-id><pub-id pub-id-type="pmid">34074005</pub-id>
</element-citation></ref><ref id="B7-vaccines-12-01445"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Celewicz</surname><given-names>A.</given-names></name>
<name><surname>Celewicz</surname><given-names>M.</given-names></name>
<name><surname>Michalczyk</surname><given-names>M.</given-names></name>
<name><surname>Wo&#x0017a;niakowska-Gondek</surname><given-names>P.</given-names></name>
<name><surname>Krejczy</surname><given-names>K.</given-names></name>
<name><surname>Misiek</surname><given-names>M.</given-names></name>
<name><surname>Rzepka</surname><given-names>R.</given-names></name>
</person-group><article-title>Pregnancy as a Risk Factor of Severe COVID-19</article-title><source>J. Clin. Med.</source><year>2021</year><volume>10</volume><elocation-id>5458</elocation-id><pub-id pub-id-type="doi">10.3390/jcm10225458</pub-id><pub-id pub-id-type="pmid">34830740</pub-id>
</element-citation></ref><ref id="B8-vaccines-12-01445"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>L.H.</given-names></name>
<name><surname>Dollinger</surname><given-names>C.Y.</given-names></name>
<name><surname>VanderWeele</surname><given-names>T.J.</given-names></name>
<name><surname>Wyszynski</surname><given-names>D.F.</given-names></name>
<name><surname>Hern&#x000e1;ndez-D&#x000ed;az</surname><given-names>S.</given-names></name>
</person-group><article-title>Timing and severity of COVID-19 during pregnancy and risk of preterm birth in the International Registry of Coronavirus Exposure in Pregnancy</article-title><source>BMC Pregnancy Childbirth</source><year>2022</year><volume>22</volume><elocation-id>775</elocation-id><pub-id pub-id-type="doi">10.1186/s12884-022-05101-3</pub-id><pub-id pub-id-type="pmid">36258186</pub-id>
</element-citation></ref><ref id="B9-vaccines-12-01445"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vouga</surname><given-names>M.</given-names></name>
<name><surname>Favre</surname><given-names>G.</given-names></name>
<name><surname>Martinez-Perez</surname><given-names>O.</given-names></name>
<name><surname>Pomar</surname><given-names>L.</given-names></name>
<name><surname>Acebal</surname><given-names>L.F.</given-names></name>
<name><surname>Abascal-Saiz</surname><given-names>A.</given-names></name>
<name><surname>Hernandez</surname><given-names>M.R.V.</given-names></name>
<name><surname>Hcini</surname><given-names>N.</given-names></name>
<name><surname>Lambert</surname><given-names>V.</given-names></name>
<name><surname>Carles</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Maternal outcomes and risk factors for COVID-19 severity among pregnant women</article-title><source>Nat. Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>13898</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-92357-y</pub-id></element-citation></ref><ref id="B10-vaccines-12-01445"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Man</surname><given-names>O.M.</given-names></name>
<name><surname>Azamor</surname><given-names>T.</given-names></name>
<name><surname>Cambou</surname><given-names>M.C.</given-names></name>
<name><surname>Fuller</surname><given-names>T.L.</given-names></name>
<name><surname>Kerin</surname><given-names>T.</given-names></name>
<name><surname>Paiola</surname><given-names>S.G.</given-names></name>
<name><surname>Cranston</surname><given-names>J.S.</given-names></name>
<name><surname>Mok</surname><given-names>T.</given-names></name>
<name><surname>Rao</surname><given-names>R.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Respiratory distress in SARS-CoV-2 exposed uninfected neonates followed in the COVID Outcomes in Mother-Infant Pairs (COMP) Study</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>399</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-44549-5</pub-id><pub-id pub-id-type="pmid">38267411</pub-id>
</element-citation></ref><ref id="B11-vaccines-12-01445"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tavares Veras Florentino</surname><given-names>P.</given-names></name>
<name><surname>Cerqueira-Silva</surname><given-names>T.</given-names></name>
<name><surname>Freire De Carvalho</surname><given-names>L.</given-names></name>
<name><surname>J&#x000f4;se Oliveira Alves</surname><given-names>F.</given-names></name>
<name><surname>De Ara&#x000fa;jo Oliveira</surname><given-names>V.</given-names></name>
<name><surname>Mateus Oliveira Aguilar</surname><given-names>G.</given-names></name>
<name><surname>De Sousa Prado</surname><given-names>R.</given-names></name>
<name><surname>Soranz</surname><given-names>D.</given-names></name>
<name><surname>Pearce</surname><given-names>N.</given-names></name>
<name><surname>Boaventura</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Safety of BNT162b2 and CoronaVac during pregnancy on birth outcomes and neonatal mortality: A cohort study from Brazil</article-title><source>Int. J. Epidemiol.</source><year>2023</year><volume>52</volume><fpage>1708</fpage><lpage>1715</lpage><pub-id pub-id-type="doi">10.1093/ije/dyad120</pub-id><pub-id pub-id-type="pmid">37690066</pub-id>
</element-citation></ref><ref id="B12-vaccines-12-01445"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brendolin</surname><given-names>M.</given-names></name>
<name><surname>Fuller</surname><given-names>T.</given-names></name>
<name><surname>Wakimoto</surname><given-names>M.</given-names></name>
<name><surname>Rangel</surname><given-names>L.</given-names></name>
<name><surname>Rodrigues</surname><given-names>G.M.</given-names></name>
<name><surname>Rohloff</surname><given-names>R.D.</given-names></name>
<name><surname>Guaraldo</surname><given-names>L.</given-names></name>
<name><surname>Nielsen-Saines</surname><given-names>K.</given-names></name>
<name><surname>Brasil</surname><given-names>P.</given-names></name>
</person-group><article-title>Severe maternal morbidity and mortality during the COVID-19 pandemic: A cohort study in Rio de Janeiro</article-title><source>IJID Reg.</source><year>2022</year><volume>6</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.ijregi.2022.11.004</pub-id><pub-id pub-id-type="pmid">36407853</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01445"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahmati</surname><given-names>M.</given-names></name>
<name><surname>Yon</surname><given-names>D.K.</given-names></name>
<name><surname>Lee</surname><given-names>S.W.</given-names></name>
<name><surname>Butler</surname><given-names>L.</given-names></name>
<name><surname>Koyanagi</surname><given-names>A.</given-names></name>
<name><surname>Jacob</surname><given-names>L.</given-names></name>
<name><surname>Shin</surname><given-names>J.I.</given-names></name>
<name><surname>Smith</surname><given-names>L.</given-names></name>
</person-group><article-title>Effects of COVID-19 vaccination during pregnancy on SARS-CoV-2 infection and maternal and neonatal outcomes: A systematic review and meta-analysis</article-title><source>Rev. Med. Virol.</source><year>2023</year><volume>33</volume><fpage>e2434</fpage><pub-id pub-id-type="doi">10.1002/rmv.2434</pub-id><pub-id pub-id-type="pmid">36896895</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01445"><label>14.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Berman Institute of Bioethics &#x00026; Center for Immunization Research, Johns Hopkins University</collab>
</person-group><article-title>COVID-19 Maternal Immunization Tracker (COMIT)</article-title><comment>Available online: <ext-link xlink:href="http://www.comitglobal.org" ext-link-type="uri">http://www.comitglobal.org</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-04">(accessed on 4 October 2024)</date-in-citation></element-citation></ref><ref id="B15-vaccines-12-01445"><label>15.</label><element-citation publication-type="webpage"><article-title>COVID-19 Vaccines and Pregnancy: Conversation Guide for Clinicians</article-title><comment>Available online: <ext-link xlink:href="https://www.acog.org/covid-19/covid-19-vaccines-and-pregnancy-conversation-guide-for-clinicians" ext-link-type="uri">https://www.acog.org/covid-19/covid-19-vaccines-and-pregnancy-conversation-guide-for-clinicians</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-01-10">(accessed on 10 January 2024)</date-in-citation></element-citation></ref><ref id="B16-vaccines-12-01445"><label>16.</label><element-citation publication-type="gov"><article-title>SIVEP-Gripe-Notifica&#x000e7;&#x000f5;es de S&#x000ed;ndromes Respirat&#x000f3;rias Agudas Graves (SRAG)-Rio de Janeiro-Dados Completos</article-title><comment>Available online: <ext-link xlink:href="https://sistemas.saude.rj.gov.br/tabnetbd/dhx.exe?sivep_gripe/sivep_gripe.def" ext-link-type="uri">https://sistemas.saude.rj.gov.br/tabnetbd/dhx.exe?sivep_gripe/sivep_gripe.def</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-01">(accessed on 1 February 2024)</date-in-citation></element-citation></ref><ref id="B17-vaccines-12-01445"><label>17.</label><element-citation publication-type="gov"><article-title>Notifies-DATASUS</article-title><comment>Available online: <ext-link xlink:href="https://datasus.saude.gov.br/notifica/" ext-link-type="uri">https://datasus.saude.gov.br/notifica/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-01">(accessed on 1 February 2024)</date-in-citation></element-citation></ref><ref id="B18-vaccines-12-01445"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kobayashi</surname><given-names>C.D.</given-names></name>
<name><surname>Porto</surname><given-names>V.B.G.</given-names></name>
<name><surname>da N&#x000f3;brega</surname><given-names>M.E.B.</given-names></name>
<name><surname>Cabral</surname><given-names>C.M.</given-names></name>
<name><surname>Barros</surname><given-names>T.D.</given-names></name>
<name><surname>Martins</surname><given-names>C.M.R.</given-names></name>
</person-group><article-title>Adverse Events Related to COVID-19 Vaccines Reported in Pregnant Women in Brazil</article-title><source>Rev. Bras. Ginecol. Obs.</source><year>2022</year><volume>44</volume><fpage>821</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1055/s-0042-1755461</pub-id></element-citation></ref><ref id="B19-vaccines-12-01445"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Metz</surname><given-names>T.D.</given-names></name>
<name><surname>Clifton</surname><given-names>R.G.</given-names></name>
<name><surname>Hughes</surname><given-names>B.L.</given-names></name>
<name><surname>Sandoval</surname><given-names>G.J.</given-names></name>
<name><surname>Grobman</surname><given-names>W.A.</given-names></name>
<name><surname>Saade</surname><given-names>G.R.</given-names></name>
<name><surname>Manuck</surname><given-names>T.A.</given-names></name>
<name><surname>Longo</surname><given-names>M.</given-names></name>
<name><surname>Sowles</surname><given-names>A.</given-names></name>
<name><surname>Clark</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network. Association of SARS-CoV-2 Infection With Serious Maternal Morbidity and Mortality From Obstetric Complications</article-title><source>JAMA</source><year>2022</year><volume>327</volume><fpage>748</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.1190</pub-id><pub-id pub-id-type="pmid">35129581</pub-id>
</element-citation></ref><ref id="B20-vaccines-12-01445"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zou</surname><given-names>G.</given-names></name>
</person-group><article-title>A modified poisson regression approach to prospective studies with binary data</article-title><source>Am. J. Epidemiol.</source><year>2004</year><volume>159</volume><fpage>702</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1093/aje/kwh090</pub-id><pub-id pub-id-type="pmid">15033648</pub-id>
</element-citation></ref><ref id="B21-vaccines-12-01445"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Westreich</surname><given-names>D.</given-names></name>
<name><surname>Greenland</surname><given-names>S.</given-names></name>
</person-group><article-title>The table 2 fallacy: Presenting and interpreting confounder and modifier coefficients</article-title><source>Am. J. Epidemiol.</source><year>2013</year><volume>177</volume><fpage>292</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1093/aje/kws412</pub-id><pub-id pub-id-type="pmid">23371353</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01445"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rudey</surname><given-names>E.L.</given-names></name>
<name><surname>Leal</surname><given-names>M.D.C.</given-names></name>
<name><surname>Rego</surname><given-names>G.</given-names></name>
</person-group><article-title>Cesarean section rates in Brazil: Trend analysis using the Robson classification system</article-title><source>Medicine</source><year>2020</year><volume>99</volume><fpage>e19880</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000019880</pub-id><pub-id pub-id-type="pmid">32332659</pub-id>
</element-citation></ref><ref id="B23-vaccines-12-01445"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Auger</surname><given-names>N.</given-names></name>
<name><surname>Ukah</surname><given-names>U.V.</given-names></name>
<name><surname>Wei</surname><given-names>S.Q.</given-names></name>
<name><surname>Healy-Profit&#x000f3;s</surname><given-names>J.</given-names></name>
<name><surname>Lo</surname><given-names>E.</given-names></name>
<name><surname>Dayan</surname><given-names>N.</given-names></name>
</person-group><article-title>Impact of COVID-19 on risk of severe maternal morbidity</article-title><source>Crit. Care</source><year>2023</year><volume>27</volume><fpage>344</fpage><pub-id pub-id-type="doi">10.1186/s13054-023-04584-6</pub-id><pub-id pub-id-type="pmid">37670329</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01445"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gulersen</surname><given-names>M.</given-names></name>
<name><surname>Rochelson</surname><given-names>B.</given-names></name>
<name><surname>Shan</surname><given-names>W.</given-names></name>
<name><surname>Wetcher</surname><given-names>C.S.</given-names></name>
<name><surname>Nimaroff</surname><given-names>M.</given-names></name>
<name><surname>Blitz</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Severe maternal morbidity in pregnant patients with SARS-CoV-2 infection</article-title><source>Am. J. Obs. Gynecol. MFM</source><year>2022</year><volume>4</volume><fpage>100636</fpage><pub-id pub-id-type="doi">10.1016/j.ajogmf.2022.100636</pub-id><pub-id pub-id-type="pmid">35398348</pub-id>
</element-citation></ref><ref id="B25-vaccines-12-01445"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lapinsky</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Acute respiratory failure in pregnancy</article-title><source>Obs. Med.</source><year>2015</year><volume>8</volume><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1177/1753495X15589223</pub-id><pub-id pub-id-type="pmid">27512467</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01445"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wastnedge</surname><given-names>E.A.</given-names></name>
<name><surname>Reynolds</surname><given-names>R.M.</given-names></name>
<name><surname>Van Boeckel</surname><given-names>S.R.</given-names></name>
<name><surname>Stock</surname><given-names>S.J.</given-names></name>
<name><surname>Denison</surname><given-names>F.C.</given-names></name>
<name><surname>Maybin</surname><given-names>J.A.</given-names></name>
<name><surname>Critchley</surname><given-names>H.O.</given-names></name>
</person-group><article-title>Pregnancy and COVID-19</article-title><source>Physiol. Rev.</source><year>2021</year><volume>101</volume><fpage>303</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1152/physrev.00024.2020</pub-id><pub-id pub-id-type="pmid">32969772</pub-id>
</element-citation></ref><ref id="B27-vaccines-12-01445"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>N.</given-names></name>
<name><surname>Bhatia</surname><given-names>V.</given-names></name>
</person-group><article-title>Maternal SARS-CoV-2 Infection, its Vertical Transmission, and Impact on Overall Perinatal Outcomes: A Narrative Review</article-title><source>Curr. Pediatr. Rev.</source><year>2022</year><volume>18</volume><fpage>103</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.2174/1573396317666211124095020</pub-id><pub-id pub-id-type="pmid">34819008</pub-id>
</element-citation></ref><ref id="B28-vaccines-12-01445"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foo</surname><given-names>S.-S.</given-names></name>
<name><surname>Cambou</surname><given-names>M.C.</given-names></name>
<name><surname>Mok</surname><given-names>T.</given-names></name>
<name><surname>Fajardo</surname><given-names>V.M.</given-names></name>
<name><surname>Jung</surname><given-names>K.L.</given-names></name>
<name><surname>Fuller</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Kerin</surname><given-names>T.</given-names></name>
<name><surname>Mei</surname><given-names>J.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>The systemic inflammatory landscape of COVID-19 in pregnancy: Extensive serum proteomic profiling of mother-infant dyads with in utero SARS-CoV-2</article-title><source>Cell Rep. Med.</source><year>2021</year><volume>2</volume><fpage>100453</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100453</pub-id><pub-id pub-id-type="pmid">34723226</pub-id>
</element-citation></ref><ref id="B29-vaccines-12-01445"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shanes</surname><given-names>E.D.</given-names></name>
<name><surname>Mithal</surname><given-names>L.B.</given-names></name>
<name><surname>Otero</surname><given-names>S.</given-names></name>
<name><surname>Azad</surname><given-names>H.A.</given-names></name>
<name><surname>Miller</surname><given-names>E.S.</given-names></name>
<name><surname>Goldstein</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Placental pathology in COVID-19</article-title><source>Am. J. Clin. Pathol.</source><year>2020</year><volume>154</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1093/ajcp/aqaa089</pub-id><pub-id pub-id-type="pmid">32441303</pub-id>
</element-citation></ref><ref id="B30-vaccines-12-01445"><label>30.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>CDC</collab>
</person-group><article-title>Benefits of Getting a COVID-19 Vaccine. Centers for Disease Control and Prevention</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html" ext-link-type="uri">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-01">(accessed on 1 February 2024)</date-in-citation></element-citation></ref><ref id="B31-vaccines-12-01445"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vardhana</surname><given-names>S.</given-names></name>
<name><surname>Baldo</surname><given-names>L.</given-names></name>
<name><surname>Morice</surname><given-names>W.G.</given-names><suffix>2nd</suffix></name>
<name><surname>Wherry</surname><given-names>E.J.</given-names></name>
</person-group><article-title>Understanding T cell responses to COVID-19 is essential for informing public health strategies</article-title><source>Sci. Immunol.</source><year>2022</year><volume>7</volume><fpage>eabo1303</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.abo1303</pub-id><pub-id pub-id-type="pmid">35324269</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01445"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bridwell</surname><given-names>R.E.</given-names></name>
<name><surname>Carius</surname><given-names>B.M.</given-names></name>
<name><surname>Long</surname><given-names>B.</given-names></name>
<name><surname>Oliver</surname><given-names>J.J.</given-names></name>
<name><surname>Schmitz</surname><given-names>G.</given-names></name>
</person-group><article-title>Sepsis in Pregnancy: Recognition and Resuscitation</article-title><source>West. J. Emerg. Med.</source><year>2019</year><volume>20</volume><fpage>822</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.5811/westjem.2019.6.43369</pub-id><pub-id pub-id-type="pmid">31539341</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01445"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Otero</surname><given-names>S.</given-names></name>
<name><surname>Miller</surname><given-names>E.S.</given-names></name>
<name><surname>Sunderraj</surname><given-names>A.</given-names></name>
<name><surname>Shanes</surname><given-names>E.D.</given-names></name>
<name><surname>Sakowicz</surname><given-names>A.</given-names></name>
<name><surname>Goldstein</surname><given-names>J.A.</given-names></name>
<name><surname>Mithal</surname><given-names>L.B.</given-names></name>
</person-group><article-title>Maternal Antibody Response and Transplacental Transfer Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection or Vaccination in Pregnancy</article-title><source>Clin. Infect. Dis.</source><year>2023</year><volume>76</volume><fpage>220</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac793</pub-id><pub-id pub-id-type="pmid">36348510</pub-id>
</element-citation></ref><ref id="B34-vaccines-12-01445"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cambou</surname><given-names>M.C.</given-names></name>
<name><surname>Liu</surname><given-names>C.M.</given-names></name>
<name><surname>Mok</surname><given-names>T.</given-names></name>
<name><surname>Fajardo-Martinez</surname><given-names>V.</given-names></name>
<name><surname>Paiola</surname><given-names>S.G.</given-names></name>
<name><surname>Ibarrondo</surname><given-names>F.J.</given-names></name>
<name><surname>Kerin</surname><given-names>T.</given-names></name>
<name><surname>Fuller</surname><given-names>T.</given-names></name>
<name><surname>Tobin</surname><given-names>N.H.</given-names></name>
<name><surname>Garcia</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Longitudinal Evaluation of Antibody Persistence in Mother-Infant Dyads After Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Pregnancy</article-title><source>J. Infect. Dis.</source><year>2023</year><volume>227</volume><fpage>236</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac366</pub-id><pub-id pub-id-type="pmid">36082433</pub-id>
</element-citation></ref><ref id="B35-vaccines-12-01445"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Halasa</surname><given-names>N.B.</given-names></name>
<name><surname>Olson</surname><given-names>S.M.</given-names></name>
<name><surname>Staat</surname><given-names>M.A.</given-names></name>
<name><surname>Newhams</surname><given-names>M.M.</given-names></name>
<name><surname>Price</surname><given-names>A.M.</given-names></name>
<name><surname>Pannaraj</surname><given-names>P.S.</given-names></name>
<name><surname>Boom</surname><given-names>J.A.</given-names></name>
<name><surname>Sahni</surname><given-names>L.C.</given-names></name>
<name><surname>Chiotos</surname><given-names>K.</given-names></name>
<name><surname>Cameron</surname><given-names>M.A.</given-names></name>
<etal/>
</person-group><article-title>Maternal Vaccination and Risk of Hospitalization for COVID-19 among Infants</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>387</volume><fpage>109</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2204399</pub-id><pub-id pub-id-type="pmid">35731908</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01445-f001"><label>Figure 1</label><caption><p>Patient selection cascade among SARS-CoV-2 positive and negative pregnant patients.</p></caption><graphic xlink:href="vaccines-12-01445-g001" position="float"/></fig><table-wrap position="float" id="vaccines-12-01445-t001"><object-id pub-id-type="pii">vaccines-12-01445-t001_Table 1</object-id><label>Table 1</label><caption><p>Maternal and infant demographics and clinical history for pregnancies evaluated for SARS-CoV-2 during hospitalization (during pregnancy or in the post-partum period) between March 2020 and March 2023.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">All Pregnancies<break/><italic toggle="yes">n</italic> = 524 (%)</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 Positive<break/><italic toggle="yes">n</italic> = 275 (%)</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 Negative<break/><italic toggle="yes">n</italic> = 249 (%)</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value <sup>a</sup></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at time of hospitalization</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003c;18 </td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">19 (3.6)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">7 (2.6)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">12 (4.8)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.110 <sup>b</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;18&#x02013;34</td><td align="center" valign="top" rowspan="1" colspan="1">398 (76.0)</td><td align="center" valign="top" rowspan="1" colspan="1">204 (74.2)</td><td align="center" valign="top" rowspan="1" colspan="1">194 (77.9)</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02265;35 </td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">107 (20.4)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">64 (23.3)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">43 (17.3)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Region</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;Urban </td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">375 (71.6)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">184 (66.9)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">191 (76.7)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.001 <sup>b</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Greater metropolitan region </td><td align="center" valign="top" rowspan="1" colspan="1">126 (24.4)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (25.8)</td><td align="center" valign="top" rowspan="1" colspan="1">55 (22.1)</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;Rural region/outskirts </td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">23 (4.4)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">20 (7.3)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">3 (1.2)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003; Black </td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">103 (19.7)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">61 (22.2)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">42 (16.9)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.267 <sup>b</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003; Multiracial </td><td align="center" valign="top" rowspan="1" colspan="1">67 (12.8)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (11.6)</td><td align="center" valign="top" rowspan="1" colspan="1">35 (14.1)</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003; White </td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">354 (67.6)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">182 (66.2)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">172 (69.1)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education level</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">None or Unknown</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">4 (0.8)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1 (0.4)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">3 (1.2)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.085 <sup>b</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Less than high school </td><td align="center" valign="top" rowspan="1" colspan="1">266 (50.8)</td><td align="center" valign="top" rowspan="1" colspan="1">130 (47.3)</td><td align="center" valign="top" rowspan="1" colspan="1">136 (54.6)</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">High school completion</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">214 (40.8)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">117 (42.6)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">97 (39.0)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">University completion</td><td align="center" valign="top" rowspan="1" colspan="1">40 (7.6)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (9.8)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (5.2)</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of delivery </td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vaginal</td><td align="center" valign="top" rowspan="1" colspan="1">264 (50.4)</td><td align="center" valign="top" rowspan="1" colspan="1">137 (52.5)</td><td align="center" valign="top" rowspan="1" colspan="1">127 (52.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.998 <sup>b</sup></td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">C-section</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">239 (45.6)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">124 (47.5)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">115 (47.5)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gravida </td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003; Primigravid</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">178 (34.0)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">96 (34.9)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">82 (32.9)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.633 <sup>b</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003; Multigravid</td><td align="center" valign="top" rowspan="1" colspan="1">346 (66.0)</td><td align="center" valign="top" rowspan="1" colspan="1">179 (65.1)</td><td align="center" valign="top" rowspan="1" colspan="1">167 (67.1)</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Twin gestation </td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">13 (2.5)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">7 (2.7)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">6 (2.5)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.886 <sup>c</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Maternal Comorbidities </td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pre-existing systems disorders</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">49 (19.3)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">24 (8.7)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">25 (10.0)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.606 <sup>c</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Immunodeficiencies + HIV</td><td align="center" valign="top" rowspan="1" colspan="1">21 (4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (4.4)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (3.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.662 <sup>c</sup></td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pulmonary disease + asthma</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">74 (14.1)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">36 (13.1)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">38 (15.3)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.476 <sup>c</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Obesity (pre-pregnancy BMI &#x0003e; 30)</td><td align="center" valign="top" rowspan="1" colspan="1">114 (21.8)</td><td align="center" valign="top" rowspan="1" colspan="1">59 (21.5)</td><td align="center" valign="top" rowspan="1" colspan="1">55 (22.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.861 <sup>c</sup></td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Hypertension (pre-existing)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">99 (18.9)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">53 (19.3)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">46 (18.5)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.816 <sup>c</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes (pre-existing)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (2.9)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (3.6)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.264 <sup>c</sup></td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Smoking (current or Hx)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">96 (18.3)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">34 (12.4)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">62 (24.9)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.001 <sup>c</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">COVID-19 vaccination doses</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;No vaccination</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">272 (51.9)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">148 (53.8)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">124 (49.8)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.358 <sup>c</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;At least 1 vaccination </td><td align="center" valign="top" rowspan="1" colspan="1">252 (48.1)</td><td align="center" valign="top" rowspan="1" colspan="1">127 (46.2)</td><td align="center" valign="top" rowspan="1" colspan="1">125 (50.2)</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine type (first and/or second dose) <sup>d</sup></td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pfizer </td><td align="center" valign="top" rowspan="1" colspan="1">172 (68.3)</td><td align="center" valign="top" rowspan="1" colspan="1">85 (67.0)</td><td align="center" valign="top" rowspan="1" colspan="1">87 (69.6)</td><td rowspan="4" align="center" valign="top" style="border-bottom:solid thin" colspan="1">0.520 <sup>b</sup></td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sinovac </td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">48 (19.0)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">22 (17.3)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">26 (20.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Johnson and Johnson</td><td align="center" valign="top" rowspan="1" colspan="1">3 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.8)</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Oxford-AstraZeneca Covishield </td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">29 (11.5)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">18 (14.1)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">11 (8.8)</td></tr></tbody></table><table-wrap-foot><fn><p>a. Bivariate associations between socio-demographics and clinical outcomes with SARS-CoV-2 infection were assessed through Chi-square tests of independence. b. Comparisons conducted among categorical variable (i.e., belongs to one of the groups) distributions of SARS-CoV-2 exposed group versus non-exposed groups. c. Comparisons conducted between dichotomous variable (i.e., no versus yes for the characteristic) distributions of SARS-CoV-2 exposed group versus non-exposed groups. d. Among those vaccinated (n = 252).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01445-t002"><object-id pub-id-type="pii">vaccines-12-01445-t002_Table 2</object-id><label>Table 2</label><caption><p>Selected maternal and infant outcomes during hospitalization (during pregnancy or in the post-partum period) between March 2020 and March 2023.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">All Pregnancies<break/><italic toggle="yes">n</italic> = 524 (%)</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 Positive<break/><italic toggle="yes">n</italic> = 275 (%)</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 Negative<break/><italic toggle="yes">n</italic> = 249 (%)</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value <sup>a</sup></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertensive disorders in pregnancy</td><td align="center" valign="top" rowspan="1" colspan="1">171 (32.6)</td><td align="center" valign="top" rowspan="1" colspan="1">82 (29.8)</td><td align="center" valign="top" rowspan="1" colspan="1">89 (35.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.149 <sup>c</sup></td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Postpartum hemorrhage</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">73 (13.9)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">36 (13.1)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">37 (14.9)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.559 <sup>c</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Maternal sepsis</td><td align="center" valign="top" rowspan="1" colspan="1">23 (4.4)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (4.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.648 <sup>c</sup></td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gestational age at time of delivery (n = 532) </td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02005;&#x02005;&#x0003c;37 weeks</td><td align="center" valign="top" rowspan="1" colspan="1">130 (24.8)</td><td align="center" valign="top" rowspan="1" colspan="1">72 (27.6)</td><td align="center" valign="top" rowspan="1" colspan="1">58 (24.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.354 <sup>b</sup></td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02005;&#x02005;37&#x02013;41 weeks</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">373 (71.2)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">189 (72.4)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">184 (76.0)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Birth outcomes (n = 553)</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stillbirths&#x02019; </td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">11 (2.1)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">6 (2.2)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">5 (2.0)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.407 <sup>b</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Miscarriages (&#x0003c;20 weeks) </td><td align="center" valign="top" rowspan="1" colspan="1">21 (4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (5.1)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (2.8) </td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Live birth </td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">492 (93.9)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">255 (92.7)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">237 (95.2)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Maternal outcomes </td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ICU admission (yes/no)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">35 (6.7)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">24 (8.7)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">11 (4.4)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.048 <sup>c</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ventilator support</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No support</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">402 (76.7)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">199 (72.4)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">203 (81.5)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.005 <sup>b</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non-invasive </td><td align="center" valign="top" rowspan="1" colspan="1">93 (17.7)</td><td align="center" valign="top" rowspan="1" colspan="1">52 (18.9)</td><td align="center" valign="top" rowspan="1" colspan="1">41 (16.5)</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Invasive </td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">26 (5.0)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">22 (8.0)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">4 (1.6)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Maternal Death</td><td align="center" valign="top" rowspan="1" colspan="1">5 (1.0)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (1.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.216 <sup>c</sup></td></tr><tr><td colspan="5" align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Neonatal outcomes </td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fetal sex (n = 515)</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02005;Male</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">279 (54.2)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">143 (53.4)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">136 (55.1)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.698 <sup>b</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02005;Female</td><td align="center" valign="top" rowspan="1" colspan="1">236 (45.8)</td><td align="center" valign="top" rowspan="1" colspan="1">125 (46.6)</td><td align="center" valign="top" rowspan="1" colspan="1">111 (44.9)</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NICU-admission (n = 503)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">157 (31.2)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">93 (35.6)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">64 (26.5)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.026 <sup>c</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Neonatal Respiratory Distress (n = 503)</td><td align="center" valign="top" rowspan="1" colspan="1">123 (25.1)</td><td align="center" valign="top" rowspan="1" colspan="1">68 (26.1)</td><td align="center" valign="top" rowspan="1" colspan="1">58 (23.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.589 <sup>c</sup></td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Size for gestational age (n = 499)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Appropriate growth </td><td align="center" valign="top" rowspan="1" colspan="1">380 (76.2)</td><td align="center" valign="top" rowspan="1" colspan="1">200 (77.5)</td><td align="center" valign="top" rowspan="1" colspan="1">180 (74.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.458 <sup>b</sup></td></tr><tr><td align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SGA/LGA</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">119 (23.8)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">58 (22.5)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">61 (25.3)</td><td align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>a. Bivariate associations between selected maternal and infant outcomes with SARS-CoV-2 infection were assessed through Chi-square tests of independence. b. Comparisons conducted among categorical variable (i.e., belongs to one of the groups) distributions of SARS-CoV-2 exposed group versus non-exposed groups. c. Comparisons conducted between dichotomous variable (i.e., no versus yes for the characteristic) distributions of SARS-CoV-2 exposed group versus non-exposed groups.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01445-t003"><object-id pub-id-type="pii">vaccines-12-01445-t003_Table 3</object-id><label>Table 3</label><caption><p>Associations between maternal SARS-CoV-2 infection and at receipt of at least one maternal SARS-CoV-2 vaccination and selected outcomes. Significant adjusted RR for SARS-CoV-2 infection and SARS-CoV-2 vaccination are shown.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcome</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Unadjusted RR (95% CI)<break/>Exposure: SARS-CoV-2 Infection</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjusted RR (95% CI)<break/>Exposure: SARS-CoV-2 Infection</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Unadjusted RR (95% CI)<break/>Exposure: At Least One COVID-19 Vaccine Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjusted RR (95% CI)<break/>Exposure: At Least One COVID-19 Vaccine Dose</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypertensive disorders in pregnancy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.87 (0.73&#x02013;1.05)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.19 (0.99&#x02013;1.42)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Postpartum hemorrhage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.93 (0.73&#x02013;1.19)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.77 (0.57&#x02013;1.05)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maternal sepsis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.91 (0.59&#x02013;1.40)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17 (0.46&#x02013;0.66)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.14 (0.03&#x02013;0.56)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preterm birth</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.09 (0.91&#x02013;1.31)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.31 (1.04&#x02013;1.66)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fetal demise</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.21 (0.91&#x02013;1.60)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.77 (0.49&#x02013;1.21)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICU admission</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.34 (1.05&#x02013;1.70)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.28 (0.12&#x02013;0.64)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.27 (0.10&#x02013;0.68)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maternal Ventilator support</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.23 (1.06&#x02013;1.49)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.48 (1.08&#x02013;2.03)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.62 (0.47&#x02013;0.82)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.60 (0.43&#x02013;0.84)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Birthweight (SGA or LGA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.93 (0.75&#x02013;1.14)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.83 (0.65&#x02013;1.06)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NICU-admission (n = 520)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.22 (1.03&#x02013;1.45)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.65 (0.52&#x02013;0.82)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.62 (0.47&#x02013;0.82)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neonatal Respiratory Distress (n = 520)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.05 (0.87&#x02013;1.27)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.65 (0.51&#x02013;0.85)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.60 (0.43&#x02013;0.83)</td></tr></tbody></table><table-wrap-foot><fn><p>SARS-CoV-2 vaccination was defined as having at least 1 dose of vaccine administered prior to hospitalization. Each outcome of interest was analyzed in individual multivariate models, controlling for age, parity, gestational age, preexisting comorbidities, as well as the exposures of interest (i.e., SARS-CoV-2 infection and COVID-19 vaccination). Adjusted RRs for SARS-CoV-2 infection and COVID-19 vaccination are derived from each of the models.</p></fn></table-wrap-foot></table-wrap></floats-group></article>